Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Las Rías Medical Center
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07588438CT.gov Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | — | Recruiting | — | — | — |
NCT07567378CT.gov CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry | — | Not Yet Recruiting | — | — | — |
NCT07492563CT.gov Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay | — | Not Yet Recruiting | — | — | — |
NCT07438444CT.gov A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | — | Recruiting | — | — | — |
NCT07417618CT.gov INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | — | Active Not Recruiting | — | — | — |
NCT07299084CT.gov A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | — | Active Not Recruiting | — | — | — |
NCT06648031CT.gov Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | — | Completed | — | — | — |
NCT06779929CT.gov Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | — | Completed | — | — | — |
NCT07096063CT.gov Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | — | Completed | — | — | — |
NCT06615700CT.gov Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus | — | Completed | — | — | — |
Show 7 more trialsShow fewer
NCT05751720CT.gov Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue | — | Unknown | — | — | — |
NCT06037252CT.gov A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity | — | Active Not Recruiting | — | — | — |
NCT07309094CT.gov Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD | — | Recruiting | — | — | — |
NCT05822544CT.gov Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes | — | Recruiting | — | — | — |
NCT05536804CT.gov A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | — | Active Not Recruiting | — | — | — |
NCT04657003CT.gov A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | — | Completed | — | — | — |
NCT04407234CT.gov A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Type 2 Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tirzepatide (this asset) | Las Rías Medical Center | Approved | BB · 69 |
| Liraglutide | RenJi Hospital | P4 | BBB |
| Exenatide | Vivani Medical, Inc | P4 | BBB |
| Dapagliflozin | Bhavya Bhavya, MD | P4 | BBB |
| Cotadutide | AstraZeneca | P2 | BBB |
| Semaglutide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Metformin | Myopharm Limited | P4 | BBB |
| Saxagliptin | Nick Giannoukakis, PhD | P4 | BBB |
| Midazolam | Pfizer | P4 | BBB |
+41 more in the Type 2 Diabetes Mellitus cohort
Other indications for Tirzepatide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 1 Diabetes Mellitus | — | P4 | BBB · 78 |
| Psoriatic Arthritis | — | P4 | BBB · 74 |
| Diastolic Heart Failure | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tirzepatide in Type 2 Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tirzepatide-type-2-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →